The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

Drug rashes can be an unwanted side effect of many medications. Learn which medications can cause these skin reactions.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

Can a robot help prepare cancer medication in a hospital pharmacy? That's what hospital pharmacist Tjerk Geersing ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The Pine Bluff Police Department is now investigating multiple pharmacy burglaries, including one where thieves took a ...

To advance this research towards commercialization, Daniel Fologea benefits from an NSF Transform grant for marketed oriented ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...